| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd7c27b9ec61781656e6f039702fd568 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-48 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-14 |
| filingDate |
2015-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_274dc6471fd17ac7b1630b0058bbaffe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_121e8fb9dcb50450e06425f5317bd33f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18e13b9a21c235bc98f12070ca59e1b4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7350d01eea2a16afecabfa61aefdc45c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d43545e57424c96683f38138caeda1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e15d041bfcd74f36f91d077d38ffc1f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1e9b5be27173a92e2a745a22e5ff6f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_06264d1e469a6e948b958d83914cf238
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_04636e9e37c591364cdd9b675f659e98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f8bbd109ed7424efd37b17d40f9af08 |
| publicationDate |
2015-12-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9199944-B2 |
| titleOfInvention |
N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer |
| abstract |
Disclosed herein are a new N2,N4-bis(4-(piperazin-1-yl)phenyl)pyrimidin-2,4-diamine derivative or a pharmaceutically acceptable salt thereof and a pharmaceutical composition for the prevention or treatment of cancers containing the same as an active ingredient. The compound of the present invention has excellent inhibitory effects against the activities of anaplastic lymphoma kinase (ALK) and activated cdc42-associated kinase (ACK1) and thus can improve the therapeutic effects on the treatment of cancer cells having anaplastic lymphoma kinase fusion proteins such as EML4-ALK and NPM-ALK, and also effectively prevent the recurrence of cancers thus being useful as a pharmaceutical composition for the prevention and treatment of cancers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10632119-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10752594-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11013741-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11529350-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015374693-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11040038-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9339502-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400091-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9623026-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10111872-B2 |
| priorityDate |
2012-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |